eHealth Radio Network Interview with Scott Megill
Leveraging Precision Medicine to Improve Lives, Reduce Healthcare Costs, and Simplify Decision-Making
CLS’ President & CEO, Scott Megill, joins eHealth Radio and the Health News Channel to discuss innovative medication safety.
Listen here or wherever you get your podcasts: coriell.com/podcast
- Who is Coriell Life Sciences (CLS)?
- How does CLS partner with the healthcare community to deliver paths to better health?
- What makes Coriell Life Sciences unique?
- How can individuals benefit from participating in CLS’ medication safety program?
- What’s the biggest opportunity for the healthcare ecosystem when it comes to personalized medicine?
Medications don’t work for everyone. Nearly one-third of U.S. adults take five or more prescription drugs and, even when taken correctly, they can be dangerous for many. Payers, providers, and patients bear the financial and physical burdens of inappropriate, ineffective drugs. Each year medication errors lead to 128,000 deaths and the costs of medication-associated errors exceed $40 billion in the U.S. alone. The cost of getting medications wrong reverberates through the healthcare service model and echoes back as wasted resources, time, and poor health.
For hundreds of medications, successful treatment is directly related to an individual’s DNA. Natural variation in our genetic code can cause the same drug to produce different effects on different people. The science of pharmacogenomics (PGx) can now assist in assessing how each person will respond to medications, however, DNA testing alone is not sufficient. That’s why Coriell Life Sciences (CLS) leverages advanced, proprietary technology to bridge the gap between genetic knowledge and clinical application. Building on six decades of research, CLS developed a cutting-edge bioinformatics solution that interprets pharmacogenomic laboratory results and couples them with traditional medication management risk factors to deliver a dynamic regimen modeling tool.
Driving innovation in precision medicine, CLS unlocks the power of genetic science to provide actionable insights for employers, payers, healthcare providers, physicians, pharmacists, laboratories, and patients, that enable more effective and efficient care.
Backed by rigorous scientific methodology, Corigen™, CLS’ population-scale medication safety program, is the most comprehensive medication safety solution on the market. This novel solution is powered by CLS’s real-time medication decision support modeling tool, GeneDose LIVE. This unique system provides physicians with updated medication risk information for their patients’ current medication regimen and offers alternatives for safer therapy, all in real-time. GeneDose LIVE also provides risk analysis of non-genetic factors such as lifestyle, drug interactions, age-related risks, and other concerns, along with a personalized medication action plan (MAP) that reveals which medications are best suited for an individual.
By matching people with the right medications, CLS enables patients to benefit from fewer hospitalizations, less unneeded testing, and reduced doctor’s visits, ultimately decreasing healthcare costs. Most importantly, CLS reduces costly trial-and-error experimentation and speeds patients’ return to good health.
Recognized as a leader in precision medicine and health innovation—including IBM’s Entrepreneur of the Year—CLS leverages its influence to advocate for the advancement of precision medicine. The organization is highly active with the American Society of Pharmacovigilance, the Personalized Medicine Coalition, a signing member of the Get the Medications Right Institute, and passionate about educating stakeholder groups through the Population Health Colloquium, Health Action Council, Employer Health Innovation Roundtable, and various other platforms.
As CLS collaborates with major healthcare providers to empower the most precise medical care, the organization is continually pushing the boundaries of what’s possible—serving as the gold standard in knowledge and understanding of pharmacogenomics.